World's first international patient receives solid tumour CAR-T therapy Satri-cel in Shanghai
July 07, 2026 | 15:23
Jiahui International Cancer Center in Shanghai treated the world's first international patient with Satri-cel, the first approved CAR-T therapy for solid tumours, marking a milestone in extending access to China's frontier oncology treatments.
OriCell's GPC3 CAR-T therapy Ori-C101 receives NMPA clearance for Phase II liver cancer trial
June 08, 2026 | 10:00
OriCell Therapeutics has announced that its proprietary GPC3-targeted autologous CAR-T therapy, Ori-C101, has received clearance from China's National Medical Products Administration to proceed to a confirmatory Phase II trial in late-line advanced hepatocellular carcinoma.
Mobile Version